Avalo Therapeutics, Inc.
AVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534120
In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
Holders of 5% or more of AVTX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Avalo Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Commodore Capital LP | 13G | 9.90%5.72M shares | New | Jun 18, 20261 filing | Jun 18, 2026 | SEC |
| TCG Crossover GP II, LLC | 13G | 7.90%3.02M shares | New | May 12, 20261 filing | May 12, 2026 | SEC |
| Farallon Capital Management, L.L.C. | 13G | 7.40%3.97M shares | New | Nov 13, 20261 filing | Nov 13, 2026 | SEC |
| Deep Track Capital, LP | 13G/A | 6.87%3.61M shares | +1.06 ppfrom 5.81% | Apr 5, 20244 filings | Aug 14, 2026 | SEC |
| BlackRock, Inc. | 13G | 6.50%3.42M shares | New | Jul 27, 20261 filing | Jul 27, 2026 | SEC |
| Ra Capital Management, L.P. | 13G/A | 6.30%3.48M shares | −3.60 ppfrom 9.90% | Aug 23, 20246 filings | Aug 14, 2026 | SEC |
| Caligan Partners LP | 13G/A | 5.90%3.16M shares | −1.30 ppfrom 7.20% | Nov 14, 20254 filings | Aug 14, 2026 | SEC |
| Affinity Asset Advisors, LLC | 13G/A | 5.50%2.90M shares | 0.00 ppfrom 5.50% | Dec 31, 20245 filings | Aug 13, 2026 | SEC |
| Biotechnology Value Fund L P | 13G/A | 5.30%2.80M shares | −4.69 ppfrom 9.99% | Aug 23, 20246 filings | Aug 14, 2026 | SEC |
| Trails Edge Capital Partners, LP | 13G | 5.20%2.80M shares | New | Oct 29, 20261 filing | Oct 29, 2026 | SEC |
| Point72 Asset Management, L.P. | 13G | 5.20%2.71M shares | +1.70 ppfrom 3.50% | Sep 21, 20218 filings | May 26, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
103 Schedule 13D and 13G filings on Avalo Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 20268:48 AM ET | Farallon Capital Management, L.L.C.and 15 others | 13G | 7.40%3.97M shares | New | Sep 30, 2026 | SEC |
| Nov 10, 20266:36 AM ET | State Street Corp | 13G | 4.80%2.56M shares | −0.70 ppfrom 5.50%Below 5% | Sep 30, 2026 | SEC |
| Nov 6, 20269:45 AM ET | FMR LLCand 1 other | 13G/A | 0.90%474.4K shares | −8.90 ppfrom 9.80%Below 5% | Oct 30, 2026 | SEC |
| Nov 5, 20261:10 PM ET | FMR LLCand 1 other | 13G/A | 9.80%5.25M shares | −1.00 ppfrom 10.80% | Sep 30, 2026 | SEC |
| Oct 29, 20264:15 PM ET | Trails Edge Capital Partners, LPand 2 others | 13G | 5.20%2.80M shares | New | Oct 22, 2026 | SEC |
| Aug 14, 20264:40 PM ET | Nantahala Capital Management, LLCand 2 others | 13G/A | 3.54%1.86M shares | −5.85 ppfrom 9.39%Below 5% | Jun 30, 2026 | SEC |
| Aug 14, 20264:40 PM ET | Caligan Partners LPand 1 other | 13G/A | 5.90%3.16M shares | −1.30 ppfrom 7.20% | Jun 30, 2026 | SEC |
| Aug 14, 20264:38 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 6.30%3.48M shares | −3.60 ppfrom 9.90% | Jun 30, 2026 | SEC |
| Aug 14, 20264:01 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 5.30%2.80M shares | −4.69 ppfrom 9.99% | Jun 30, 2026 | SEC |
| Aug 14, 202610:39 AM ET | T. Rowe Price Investment Management, Inc. | 13G/A | 0.00%3.67K shares | −9.50 ppfrom 9.50%Below 5% | Jun 30, 2026 | SEC |
| Aug 14, 20269:00 AM ET | Avoro Capital Advisors LLCand 1 other | 13G/A | 4.44%2.33M shares | −1.31 ppfrom 5.75%Below 5% | Jun 30, 2026 | SEC |
| Aug 14, 20268:24 AM ET | Deep Track Capital, LPand 2 others | 13G/A | 6.87%3.61M shares | +1.06 ppfrom 5.81% | Jun 30, 2026 | SEC |
| Aug 13, 20264:06 PM ET | Affinity Asset Advisors, LLCand 1 other | 13G/A | 5.50%2.90M shares | 0.00 ppfrom 5.50% | Jun 30, 2026 | SEC |
| Aug 7, 202611:04 AM ET | FMR LLCand 1 other | 13G/A | 10.80%5.74M shares | +1.10 ppfrom 9.70% | Jul 31, 2026 | SEC |
| Aug 7, 20268:44 AM ET | State Street Corp | 13G | 5.50%2.89M shares | New | Jun 30, 2026 | SEC |
| Aug 6, 202610:14 AM ET | FMR LLCand 1 other | 13G/A | 9.70%5.10M shares | +3.60 ppfrom 6.10% | Jun 30, 2026 | SEC |
| Jul 27, 20264:25 PM ET | BlackRock, Inc. | 13G | 6.50%3.42M shares | New | Jun 30, 2026 | SEC |
| Jul 6, 20265:29 PM ET | Millennium Management LLCand 2 others | 13G/A | 0.00%9.86K shares | −5.00 ppfrom 5.00%Below 5% | Jun 30, 2026 | SEC |
| Jun 18, 20264:29 PM ET | Commodore Capital LPand 3 others | 13G | 9.90%5.72M shares | New | Jun 11, 2026 | SEC |
| Jun 5, 202610:13 AM ET | FMR LLCand 1 other | 13G/A | 6.10%3.19M shares | −6.50 ppfrom 12.60% | May 29, 2026 | SEC |
| May 29, 20264:37 PM ET | Deep Track Capital, LPand 2 others | 13G | 5.81%3.06M shares | +5.81 ppfrom 0.00% | May 22, 2026 | SEC |
| May 26, 20265:10 PM ET | Point72 Asset Management, L.P.and 2 others | 13G | 5.20%2.71M shares | +1.70 ppfrom 3.50% | May 22, 2026 | SEC |
| May 15, 20266:41 PM ET | Logos Global Management LPand 4 others | 13G/A | 3.20%1.68M shares | −2.40 ppfrom 5.60%Below 5% | Mar 31, 2026 | SEC |
| May 15, 20264:34 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 9.90%2.46M shares | 0.00 ppfrom 9.90% | Mar 31, 2026 | SEC |
| May 15, 20264:31 PM ET | OrbiMed Advisors LLC | 13G/A | 2.10%475.2K shares | −4.30 ppfrom 6.40%Below 5% | Mar 31, 2026 | SEC |
| May 15, 20264:04 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.99%2.35M shares | 0.00 ppfrom 9.99% | Mar 31, 2026 | SEC |
| May 15, 202610:31 AM ET | Caligan Partners LPand 1 other | 13G/A | 7.20%1.64M shares | +2.30 ppfrom 4.90% | Mar 31, 2026 | SEC |
| May 15, 202610:06 AM ET | T. Rowe Price Investment Management, Inc. | 13G | 9.50%2.16M shares | New | Mar 31, 2026 | SEC |
| May 15, 20268:15 AM ET | Avoro Capital Advisors LLCand 1 other | 13G | 5.75%1.41M shares | New | Mar 31, 2026 | SEC |
| May 14, 20264:09 PM ET | Affinity Asset Advisors, LLCand 1 other | 13G/A | 5.50%1.34M shares | −0.20 ppfrom 5.70% | Mar 31, 2026 | SEC |
| May 12, 20266:09 PM ET | TCG Crossover GP II, LLCand 2 others | 13G | 7.90%3.02M shares | New | May 5, 2026 | SEC |
| May 6, 202611:00 AM ET | FMR LLCand 1 other | 13G/A | 12.60%2.88M shares | +1.10 ppfrom 11.50% | Mar 31, 2026 | SEC |
| Apr 1, 20261:02 PM ET | Logos Global Management LPand 4 others | 13G | 5.60%1.28M shares | New | Mar 26, 2026 | SEC |
| Mar 6, 202610:05 AM ET | FMR LLCand 1 other | 13G | 11.50%2.13M shares | New | Feb 27, 2026 | SEC |
| Feb 24, 20264:48 PM ET | Millennium Management LLCand 2 others | 13G | 5.00%934.4K shares | +0.20 ppfrom 4.80% | Feb 17, 2026 | SEC |
| Feb 17, 20266:13 PM ET | OrbiMed Advisors LLC | 13G/A | 6.40%1.19M shares | −2.50 ppfrom 8.90% | Dec 31, 2025 | SEC |
| Feb 17, 20265:00 PM ET | Caligan Partners LPand 1 other | 13G/A | 4.90%881.5K shares | −1.40 ppfrom 6.30%Below 5% | Dec 31, 2025 | SEC |
| Feb 17, 20264:33 PM ET | Point72 Asset Management, L.P.and 2 others | 13G/A | 3.50%627.5K shares | −4.50 ppfrom 8.00%Below 5% | Dec 31, 2025 | SEC |
| Feb 17, 20264:21 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 9.90%1.94M shares | 0.00 ppfrom 9.90% | Dec 31, 2025 | SEC |
| Feb 17, 20264:11 PM ET | Millennium Management LLCand 2 others | 13G | 4.80%887.3K shares | −0.10 ppfrom 4.90%Below 5% | Feb 10, 2026 | SEC |
| Feb 17, 20264:07 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.99%1.90M shares | 0.00 ppfrom 9.99% | Dec 31, 2025 | SEC |
| Feb 17, 20266:57 AM ET | Balyasny Asset Management LLCand 4 others | 13G/A | 2.42%439.3K shares | −3.80 ppfrom 6.22%Below 5% | Dec 31, 2025 | SEC |
| Feb 10, 20264:07 PM ET | Millennium Management LLCand 2 others | 13G | 4.90%906.8K shares | 0.00 ppfrom 4.90%Below 5% | Feb 3, 2026 | SEC |
| Feb 10, 202611:36 AM ET | Silverarc Capital Management, LLCand 1 other | 13G | 2.83%524.4K shares | −2.65 ppfrom 5.48%Below 5% | Dec 31, 2025 | SEC |
| Feb 3, 20265:19 PM ET | Millennium Management LLCand 2 others | 13G | 4.90%905.8K shares | NewBelow 5% | Jan 28, 2026 | SEC |
| Jan 30, 20261:25 PM ET | Vanguard Group Inc | 13G/A | 4.43%804.1K shares | −0.83 ppfrom 5.26%Below 5% | Dec 31, 2025 | SEC |
| Jan 29, 20267:56 PM ET | Affinity Asset Advisors, LLCand 1 other | 13G/A | 5.70%1.05M shares | −1.95 ppfrom 7.65% | Jan 22, 2026 | SEC |
| Nov 14, 20256:26 PM ET | Ikarian Capital, LLCand 1 other | 13G/A | 3.80%712.0K shares | −6.19 ppfrom 9.99%Below 5% | Sep 30, 2025 | SEC |
| Nov 14, 20254:54 PM ET | Nantahala Capital Management, LLCand 2 others | 13G/A | 9.39%1.24M shares | +0.96 ppfrom 8.43% | Sep 30, 2025 | SEC |
| Nov 14, 20254:12 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 9.90%1.39M shares | 0.00 ppfrom 9.90% | Sep 30, 2025 | SEC |
Form 144: proposed insider sales
16 notices from officers, directors and other affiliates planning to sell Avalo Therapeutics, Inc. shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| Aug 18, 20264:18 PM ET | Christopher Ryan SullivanOfficer | 31.0K | $622.2K | Aug 18, 2026 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Aug 17, 20264:49 PM ET | Mittie DoyleOfficer | 5.04K | $98.7K | Aug 17, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Aug 17, 20264:47 PM ET | Christopher Ryan SullivanOfficer | 70.7K | $1.39M | Aug 17, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Aug 17, 20264:18 PM ET | Christopher Ryan SullivanOfficer | 3.75K | $74.8K | Aug 17, 2026 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Aug 11, 20264:22 PM ET | Jennifer RileyOfficer | 2.65K | $52.0K | Aug 11, 2026 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Aug 10, 20264:47 PM ET | Mittie DoyleOfficer | 679 | $12.4K | Aug 10, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Jun 2, 20264:08 PM ET | Jonathan GoldmanDirector | 42.8K | $616.2K | Jun 2, 2026 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| May 7, 20264:20 PM ET | Christopher SullivanOfficer | 18.6K | $405.8K | May 7, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| May 6, 20264:54 PM ET | Mittie DoyleOfficer | 54.5K | $886.3K | May 6, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| May 6, 20264:32 PM ET | Christopher SullivanOfficer | 47.0K | $764.2K | May 6, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| May 6, 20264:30 PM ET | Paul VarkiOfficer | 92.8K | $1.51M | May 6, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| May 6, 20264:29 PM ET | Mitchell ChanDirector | 3.17K | $51.5K | May 6, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Apr 29, 20264:33 PM ET | Christopher SullivanOfficer | 16.9K | $217.5K | Apr 29, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Apr 6, 20264:34 PM ET | Mittie DoyleOfficer | 65.8K | $1.17M | Apr 6, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Apr 1, 20264:48 PM ET | Christopher SullivanOfficer | 16.0K | $238.3K | Apr 1, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Mar 16, 20264:39 PM ET | Mittie DoyleOfficer | 29.5K | $466.6K | Mar 16, 202610b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |